Trials / Withdrawn
WithdrawnNCT03658408
4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- Male
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if the study drug 4-aminopyridine (4-AP) can help speed up the recovery of peripheral nerve injury after prostatectomy. 4-AP is a potassium channel blocker used to improve walking in multiple sclerosis patients. Investigators will measure the effect that 4-AP may have on the recovery of sexual function and urinary incontinence after prostatectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 4-aminopyridine | Oral tablet of 2.5 mg given 4 times a day |
| DRUG | placebo | 2.5 mg sugar pill given orally 4 times a day |
Timeline
- Start date
- 2018-10-03
- Primary completion
- 2018-10-30
- Completion
- 2018-10-30
- First posted
- 2018-09-05
- Last updated
- 2018-11-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03658408. Inclusion in this directory is not an endorsement.